相关实验视频

Updated: Jun 30, 2026

Techniques to Induce and Quantify Cellular Senescence

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

MM-129通过SIRT1/STAT3信号通路对抗结肠癌中的5-甲诱导的细胞衰老

Hubert Klepacki¹, Beata Sieklucka², Joanna Kalafut³

¹Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.

|October 15, 2025

概括

药物MM-129在结直肠癌模型中对抗化疗诱导的细胞衰老. 这种老年治疗候选药物可以通过向SIRT1/STAT3通路并减少瘤复发来改善癌症治疗.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
药理学药理学是指药理学的学科.

背景情况:

细胞衰老是结直肠癌 (CRC) 发展和进展的关键因素.
五甲 (5-FU) 化疗可以诱导衰老,可能导致化学抵抗和CRC瘤复发.
研究新型老年治疗药物对于改善CRC治疗结果至关重要.

研究的目的:

为了研究5-FU对结肠癌细胞衰老的影响.
为了评估MM-129 (pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine sulfonamide) 对抗5-FU诱导的衰老的潜力.
为了阐明MM-129的老年治疗活动的潜在分子机制.

主要方法:

通过与衰老相关的β-galactosidase (SA-β-gal) 和p21表达来评估衰老.
测量了关键的衰老相关分泌表型 (SASP) 细胞因子 (IL-6,TNF-α) 和E-cadherin (CDH1).
分析了SIRT1/STAT3通路,以了解MM-129的作用机制.
实验在体外,斑马鱼外移植和DLD-1和HT-29小鼠外移植中进行.

主要成果:

在结肠癌模型中,MM-129有效抵消了5-FU诱导的衰老.
在各种模型中,MM-129降低了p21水平和SA-β-阳性细胞的数量.
MM-129抑制了SASP细胞因子 (IL-6,TNF-α),恢复了E-cadherin (CDH1),并调节了SIRT1/STAT3通路.

结论:

MM-129显示出作为结直肠癌的新型老年治疗剂的潜力.
通过准SIRT1/STAT3轴,MM-129可能会抑制SASP和亲生存信号,帮助衰老细胞清除.
将MM-129等老年疗法与传统疗法相结合,为提高CRC治疗疗效提供了一个有希望的途径.

关键词:

5 - - 甲酸是如何使用的在MM-129中,它被命名为MM-129.在SIRT1/STAT3信号传输中.细胞衰老细胞衰老化学抗药性化学抗药性是一种抗药性.结肠直肠癌是什么意思与衰老相关的分泌表现型这是一种老年治疗药物.

更多相关视频

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...